Neumora Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Neumora Therapeutics, Inc. on May 28, 2025. The filing details the voting outcomes for four proposals presented to stockholders of record as of April 28, 2025, when 161,747,922 shares of common stock were outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting results.
Material Changes and Voting Results
Stockholders voted on and approved the following proposals:
- Proposal 1 (Director Election): Elected two Class II directors. Alaa Halawa received 105,795,914 votes for, and Maykin Ho, Ph.D. received 114,262,481 votes for.
- Proposal 2 (Auditor Ratification): Ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 135,734,870 votes for.
- Proposal 3 (Option Repricing): Approved the repricing of certain outstanding stock options under the 2020 and 2023 Equity Incentive Plans. This proposal received 101,589,422 votes for, though it also saw significant opposition with 14,632,276 votes against.
- Proposal 4 (Reverse Stock Split): Approved amendments to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-30, as determined by the Board. This received 134,256,461 votes for.
Guidance, Outlook, and Risks
The filing text does not provide specific management commentary, financial guidance, or risk factors beyond the standard disclosure of the voting process. The approval of the reverse stock split indicates a strategic move to adjust the share structure, likely to meet listing requirements or improve marketability, though the specific ratio remains at the Board's discretion.
Investor Verification Checklist
- Verify the specific reverse stock split ratio selected by the Board following the authorization in Proposal 4.
- Review the Definitive Proxy Statement (Schedule 14A filed April 29, 2025) for detailed terms regarding the stock option repricing approved in Proposal 3.
- Monitor the company's stock price and trading volume post-split to assess market reaction.
- Confirm the effective date of the new auditor engagement for the 2025 fiscal year.